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ABSTRACT
The prevalence of heart failure (HF) is on the rise due to the aging of society. Furthermore, 
the continuous progress and widespread adoption of screening and diagnostic strategies 
have led to an increase in the detection rate of HF, effectively increasing the number of 
patients requiring monitoring and treatment. Because HF is associated with substantial rates 
of mortality and morbidity, as well as high socioeconomic burden, there is an increasing 
need for developing specific guidelines for HF management. The Korean guidelines for the 
diagnosis and management of chronic HF were introduced in March 2016. However, chronic 
and acute heart failure (AHF) represent distinct disease entities. Here, we introduce the 
Korean guidelines for the management of AHF with reduced or preserved ejection fraction. 
Part I of this guideline covers the definition, epidemiology, and diagnosis of AHF.
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INTRODUCTION
The number of patients with heart failure (HF) has been on the rise as a consequence of the 
aging of society and the improvement in screening and diagnostic techniques. Therefore, 
there is an increasing need for developing guidelines for the diagnosis and treatment of 
HF. Although guidelines for HF management have already been issued by American and 
European associations, many aspects of such guidelines do not reflect the domestic reality 
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KSHF Guidelines for the Management 
of Acute Heart Failure: Part I. 
Definition, Epidemiology and 
Diagnosis of Acute Heart Failure
in Korea due to the social and anthropological characteristics of the Korean population. 
Thus, to help clinicians establish the best treatment plan for Korean patients with HF, it is 
necessary to develop specific guidelines that reflect the clinical situation in Korea. In 2012, 
the Korean Society of Heart Failure (KSHF) established the Guideline Writing Committee 
to develop the treatment guidelines for HF. The Korean guidelines for the diagnosis and 
management of chronic heart failure (CHF) were introduced in March 2016.1) However, CHF 
and acute heart failure (AHF) are distinct disease entities, warranting different approaches 
for diagnosis and treatment. Here, we introduce the Korean guidelines for the management 
of AHF with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively). In Part I 
of this guideline, we discuss the definition, epidemiology, and diagnosis of AHF.
This guideline was developed based on previously issued international guidelines and 
amended to reflect the clinical situation in Korea. A committee of KSHF members decided 
on the format of the guideline, the selection of topics addressed, and the composition of 
the Writing Committee. To develop the guidelines, we considered all clinical studies and 
evidence included in the international guidelines, as well as domestic research conducted 
in Korean patients with HF. Members of the Writing Committee first drafted thematic 
manuscripts, which were then assembled and arranged according to the evidence-
based scales. To ensure transparency and facilitate future revision of the guidelines, we 
documented the process followed for issuing a recommendation for each topic based on 
the gathered evidence. The guideline was drafted, reviewed by the advisory committee, 
and finalized after receiving endorsement from the Korean Society of Cardiology, Korean 
Society of Hypertension, Korean Society of Interventional Cardiology, Korean Society of 
Echocardiography, and Korean Society of Lipid and Atherosclerosis. While working on this 
guideline, the members of the Writing Committee were not affected by external influences 
and made every effort to exclude conflicts of interests.
The Writing Committee issued the level of recommendation upon a comprehensive analysis of 
evidence from studies describing real clinical experience, from surveys, from epidemiologic, 
observational, and randomized clinical studies, and from meta-analyses. The level of 
evidence and class of recommendation were defined so as to have a clear formulation, provide 
straightforward instructions, and be easily adopted in daily clinical practice (Tables 1 and 2).
This guideline is intended to help improve clinical practice by providing recommendations 
based on clinical evidence. As such, the guideline does not serve as a basis for clinical 
judgement. The final decision in the treatment of each patient should be made by the treating 
physician according to their personal opinion and judgment, while using the guideline to 
support these decisions.
GENERAL CONCEPTS OF ACUTE HEART FAILURE
Definition and classification of acute heart failure
Definition of acute heart failure
Patients with AHF are usually hospitalized for prompt treatment because the symptoms 
manifest and worsen rapidly. “Compensated HF” is usually defined as HF that responds to 
treatment, with symptoms stable for at least 1 month. “Acute decompensated HF” is defined 
as a sudden deterioration of symptoms or signs in patients with compensated HF, whereas 
acute presentation of HF in patients with no previous symptoms is referred to as “Acute de 
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novo HF.” Acute myocardial infarction (AMI) is the most representative manifestation of 
AHF, though some patients remain asymptomatic despite decreased cardiac function or may 
exhibit gradual symptoms as decompensation develops.
Classification of acute heart failure
Although there are several ways to classify AHF, the classification based on the clinical 
condition at the time of admission is most useful from a practical perspective because it 
facilitates identification of high-risk patients and initiation of treatment according to a pre-
established treat-to-target strategy. In patients with AHF, systolic blood pressure is usually 
preserved (90–140 mmHg) or elevated (>140 mmHg; hypertensive AHF) but may also be 
decreased (<90 mmHg; hypotensive AHF). Hypotensive AHF generally has poor prognosis, 
especially if accompanied by decreased perfusion.
Regarding causes and aggravating factors of AHF, five clinical conditions require immediate 
treatment: acute coronary syndrome, hypertensive emergencies, tachycardia/severe 
bradycardia/conduction disorders, structural heart damage, and acute pulmonary embolism.
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Table 2. Formulations typically used with each class of recommendation
Class Formulation
I Should be used, is recommended, is useful/beneficial
IIa Is reasonable, can be useful/beneficial
IIb May be considered reasonable
III Is not recommended, should not be performed, is potentially harmful
Table 1. Criteria used to judge the level of evidence and establish the class of recommendation for AHF
Class Class I Class IIa Class IIb Class III
Criterion • Benefit >>> Risk • Benefit >> Risk • Benefit ≥ Risk • No benefit or harm
•  Procedure/Treatment 
SHOULD be performed
• Additional studies with 
focused objectives are needed
•  Additional studies with 
broad objectives are needed; 
collecting additional registry 
data would be helpful
•  Procedure/treatment SHOULD 
NOT BE PERFORMED as it is 
not expected to be useful or 
may even be harmful
• IT IS REASONABLE to perform 
the procedure/treatment
•  Procedure/treatment MAY BE 
CONSIDERED
Level A
•  Multiple populations 
evaluated
1)  Recommendation that 
procedure/treatment is 
useful/effective
1)  Recommendation in favor of 
procedure or treatment being 
useful/effective
1) Recommendation's 
usefulness/efficacy less well-
established
1)  Recommendation that 
procedure/treatment is not 
useful/effective and/or may 
be harmful
•  Data from multiple 
randomized clinical trials 
or meta-analyses
2)  Sufficient evidence from 
multiple randomized 
trials or meta-analyses
2)  Some conflicting evidence 
from multiple randomized 
trials or meta-analyses
2) Greater conflicting evidence 
from multiple randomized trials 
or meta-analyses
2)  Evidence from multiple 
randomized trials or meta-
analyses
Level B
•  Limited populations 
evaluated
1)  Recommendation that 
procedure/treatment is 
useful/effective
1)  Recommendation in favor of 
procedure/treatment being 
useful/effective
1)  Recommendation's 
usefulness/efficacy less well-
established
1)  Recommendation that 
procedure/treatment is not 
useful/effective or may be 
harmful
•  Data from a single 
randomized trial or 
non-randomized studies
2)  Sufficient evidence from 
a single randomized 
trial or non-randomized 
studies
2)  Some conflicting evidence 
from a single randomized trial 
or non-randomized studies
2)  Greater conflicting evidence 
from a single randomized 
trial or non-randomized 
studies
2)  Evidence from a single 
randomized trial or non-
randomized studies
Level C
•  Very limited populations 
evaluated
1)  Recommendation that 
procedure/treatment is 
useful/effective
1)  Recommendation in favor of 
procedure/treatment being 
useful/effective
1)  Recommendation's 
usefulness/efficacy less well-
established
1)  Recommendation that 
procedure or treatment is not 
useful/effective and may be 
harmful
•  Only consensus expert 
opinions, case studies, 
or standards of care
2)  Only expert opinions, 
case studies, or 
standards of care
2)  Only diverging expert 
opinions, case studies, or 
standards of care
2)  Only diverging expert 
opinions, case studies, or 
standards of care
2)  Only expert opinions, case 
studies, or standards of care
AHF = acute heart failure.
The clinical condition is defined based on the findings of the bedside physical examination, 
focused mainly on clarifying the presence, nature, and degree of congestion (“wet” or “dry”) 
and/or tissue perfusion (“warm” or “cold”) according to the Forrester classification (Figure 1). 
AHF patients can be classified into four groups with increasingly poor prognosis: group A, with 
“warm” and “dry” HF (compensated, well perfused, without congestion); group B, with “warm” 
and “wet” HF (well perfused but congested); group C, “cold” and “dry” HF (hypoperfused 
but without congestion); and group D, “cold” and “wet” HF (hypoperfused and congested). 
To confirm the presence and degree of congestion, it is necessary to assess jugular venous 
pressure and check for ascites or peripheral edema, rales or abnormal heart sound on chest 
auscultation, and pulmonary edema on chest radiography. Decreased tissue perfusion 
can be confirmed based on decreased skin temperature, reduced urine output, and altered 
mentality. Pulmonary capillary wedge pressure is the best indicator of congestion, while 
cardiac index is the best marker of perfusion.
In patients with AMI, AHF can be classified according to the Killip classification: class I, no 
clinical signs of HF; class II, HF with rales in half of the lung field and with S3 gallop; class III, 
frank acute pulmonary edema; and class IV, cardiogenic shock, hypotension, and evidence of 
peripheral vasoconstriction such as cyanosis, oliguria, and diaphoresis.
Aggravating factors, risk factors, and causes of acute heart failure
Various aggravating factors are known to induce HF decompensation (see section 2.2. 
Aggravating factors). Risk factors include concomitant diseases leading to structural heart 
disease, including hypertension, diabetes, metabolic syndrome, and atherosclerotic disease. 
Risk factors of AHF comprise myocardial disorders (coronary artery disease, hypertension, 
myocarditis, cardiomyopathy), valvular heart diseases, pericardial diseases, endocarditis, 
congenital heart disease, arrhythmia, conduction disturbance, high cardiac output state 
(anemia, sepsis, arteriovenous fistula), and right HF.
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Figure 1. Clinical classification of acute heart failure. 
CI = cardiac index; PCWP = pulmonary capillary wedge pressure.
Epidemiology
The prevalence of AHF has been increasing in parallel with the rates of cardiovascular 
disease, reflecting the aging of society and widespread adoption of a westernized lifestyle. 
AHF is a major cause of hospitalization as well as death during hospital admission and 
readmission, especially among individuals aged >65 years. The prevalence of AHF continues 
to increase despite recent advances in medical technology and reduced in-hospital mortality 
rates. According to epidemiological studies conducted in the United States, more than one 
million hospitalizations for AHF occur annually, and hospitalization rates are expected 
to continue to increase over the next 20 years.2) Approximately 15.5 million emergency 
room visits due to AHF were recorded between 1992 and 2001, with an average increase of 
18,500 cases per year.3) It is estimated that, by 2050, 20% of the population of the United 
States will consist of individuals aged >65 years, approximately 80% of whom will likely 
require hospitalization for AHF.4) While no epidemiological studies on this topic have been 
conducted in Korea, the prevalence of AHF is expected to increase in the future due to the 
recent increase in the prevalence of risk factors for cardiovascular disease, reflecting the 
westernization of eating habits, lack of physical activity, and rapid increase in the proportion 
of elderly people. AHF is also associated with a heavy socioeconomic burden. In the United 
States, the current annual cost for hospitalizations due to AHF is approximately $34 billion, 
which is similar to the figures reported in Europe.5) In Korea, AHF-related expenses associated 
with an 8-day hospital stay amount to approximately 7.7 million won (about $7,000).6)
In a Korean AHF cohort, 52% of patients were identified as having de novo HF, while the 
remaining 48% had decompensated HF.6) The same study concluded that, at the time of AHF 
diagnosis, Korean patients tended to be younger (mean age, 69 years) than those in Japan, 
USA, and Europe; the proportion of men (55%) was slightly higher among Korean AHF 
patients than among patients from AHF registries in other countries. In this Korean AHF 
cohort, 59% of patients had hypertension, 35% had diabetes, and 28% had atrial fibrillation. 
The major cause of AHF was ischemic heart disease (37%), followed by cardiomyopathies 
(21%), valvular heart disease (14%), and tachycardia-induced cardiomyopathy (11%). The 
prognosis of AHF is reportedly very poor. A study conducted in the United States reported 
a 5-year survival rate of less than 1 in 3 patients hospitalized for AHF.7) Studies conducted in 
Korea reported similarly poor outcomes: in-hospital mortality, 6.1%; short-term all-cause 
mortality, 1.2% and 9.2% at 1 and 6 months, respectively;6) long-term mortality, 15%, 21%, 
26%, and 30% at 1, 2, 3, and 4 years, respectively8); re-admission rate, 6.4% within 1 month 
and 24% within 6 months.6)
INITIAL ASSESSMENT
Symptoms and signs
The traditional clinical approach involves identifying symptoms and signs by taking a clinical 
history and performing a physical examination in all patients who visit the emergency room 
with acute symptoms suggestive of HF (Class of Recommendation, I; Level of Evidence, C). 
The diagnosis can also be made based on objective evidence of pulmonary edema or cardiac 
dysfunction in patients with signs and symptoms of AHF.9-11)
In general, symptoms and signs specific to HF can be divided into two categories: congestion 
and decreased perfusion of the peripheral tissues. AHF symptoms include orthopnea and 
paroxysmal nocturnal dyspnea as typical symptoms of congestion, as well as fatigue and 
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decreased exercise capacity associated with decreased perfusion of peripheral tissues. AHF 
signs include pulmonary edema, jugular venous engorgement, hepatic-jugular reflux reflex, 
third heart sound (S3), left downward deviation of the apical pulse, peripheral edema, and 
decreased urine output. However, it is difficult to discriminate the cause of such symptoms 
and signs, especially in patients with obesity, advanced age, and chronic lung disease.9-13) 
Therefore, it is recommended that the following medical history be recorded and physical 
examination be conducted in patients with AHF.
Orthopnea
At the bedside, the presence and severity of orthopnea can be easily evaluated if sufficient 
pillow height is used to achieve a position in which the patient can breathe comfortably. 
Thus, orthopnea can be defined as: mild or non-existent if the patient can breathe 
comfortably without a pillow or with minimal elevation of the neck: moderate if the patient 
can breathe comfortably only when using at least one pillow, with neck elevation of up to 10 
cm; and severe if the patient can breathe comfortably only when using at least two pillows.
Jugular venous distention
To evaluate jugular venous distention, the patient must sit in a relaxed posture, with the back 
at an angle of 30°–45° from the horizontal. The neck and chest should be exposed from the 
middle of the sternum to the antihelix of the ear. Upon turning the patient's neck to one side, 
jugular venous distention can be measured vertically with illumination. If it is difficult to 
distinguish the jugular venous pulse from the internal carotid pulse, the hepatojugular reflux 
can be measured by applying pressure to the right upper quadrant for about 10 seconds and 
then measuring the time it takes for jugular venous pressure to recover from the transient 
increase; if the elevated jugular venous pressure persists, right ventricular dysfunction may 
be suspected. Jugular venous distention, which is measured from the angle of Lewis to the 
highest point of internal jugular venous pulsation, is considered severe if it exceeds 15 cm.
Peripheral edema
Peripheral edema can be examined by applying pressure with the thumb for 5 seconds to 
the medial malleolus, posterior side of the tibia, or sacrum (in patients who cannot walk). 
Edema is confirmed if the skin takes longer than 10 seconds to return to the original shape, 
and is defined as mild edema if observed in only one lower limb or the sacrum, versus 
moderate edema if observed in the bilateral lower limbs. The patient is considered to have 
severe edema if a large amount of edema is noted in the lower portion of the calf, if edema 
extends from the leg to the sacrum (in immobile patients), if pitting edema develops easily 
and disappears after >30 seconds, or if acute/subacute skin changes including cutaneous 
distension or cleavage are noted.
Rales
Rales are graded as follows: grade 1, unilateral or bilateral rales across the lower third of 
the lung; grade 2, bilateral rales across the lower half or two thirds of the chest; and grade 
3, bilateral rales throughout all lung fields. It is also necessary to distinguish rales from 
wheezing (stridor) or dry crackles.
Dyspnea
Dyspnea is graded according to the New York Heart Association functional classification 
(Table 3).
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Aggravating factors of acute heart failure
In the initial evaluation of patients with AHF, it is important to perform an accurate 
hemodynamic assessment and to identify the aggravating factors. Common causes of AHF 
include: acute coronary syndrome, inappropriate control of hypertension, high salt intake, 
arrhythmia (including atrial fibrillation), medications reducing cardiac contractility, renal 
impairment, pulmonary embolism, alcohol abuse, worsening of underlying thyroid disease, 
infection, and worsening of underlying cardiovascular disease (Table  4).14)
Because acute coronary syndrome is an important factor that can cause AHF, the 
patients should be carefully checked for chest pain, changes in the ST segment on 
electrocardiography, and elevation in blood troponin levels. If necessary, coronary 
angiography should be performed to exclude the possibility of coronary artery disease as a 
cause of worsening HF.15) Hypertension is a common cause of AHF exacerbation, especially 
in women and in patients with HFpEF. Patients with HF who are taking antihypertensive 
medications can also develop AHF if they suddenly stop their medication.16)17) The symptoms 
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Table 3. New York Heart Association functional classification of dyspnea
Class Symptoms
I No limitation of daily physical activity. Ordinary physical activity does not cause symptoms.
II Slight limitation of daily physical activity. Comfortable at rest, but ordinary physical activity causes 
symptoms.
III Marked limitation of daily physical activity. Comfortable at rest, but less than ordinary activity 
causes symptoms.
IV Unable to perform any physical activity without discomfort. Symptoms of heart failure at rest. 
Discomfort increases with any physical activity.
Table 4. Causes and aggravating factors of AHF
Causes and aggravating factors
1. Acute coronary syndrome (ACS)
2. Arrhythmias (tachycardia: atrial fibrillation, ventricular tachycardia; bradycardia: conduction disturbances)
3. Excessive rise in blood pressure
4. Noncompliance with recommendations regarding low salt intake, water restriction, or medication
5. Toxic substances (alcohol, recreational drugs)
6.  Medications (e.g., non-steroidal anti-inflammatory drugs, corticosteroids, chemotherapeutics with 
cardiotoxicity)
7. Exacerbation of chronic obstructive pulmonary disease
8. Pulmonary embolism
9. Infection (including infective endocarditis)
10. Surgery and perioperative complications
11. Increased sympathetic tone, stress-induced cardiomyopathy
12.  Metabolic/hormonal derangement (e.g., diabetic ketosis, thyroid dysfunction, adrenal dysfunction, and 
pregnancy- and peripartum-related problems)
13. Damage to the cerebral arteries
14.  Acute mechanical cause: myocardial rupture complicating ACS (ventricular septal defect, pseudoaneurysm, 
free wall rupture, and acute mitral regurgitation), chest trauma or coronary artery intervention, acute native 
or prosthetic valve incompetence secondary to endocarditis, aortic dissection or thrombosis
Ponikowski P, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: 
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of 
Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, 
European Heart Journal 2016; 37 (27): 2129–2200, doi: 10.1093/eurheartj/ehw128. Reproduced by permission of 
Oxford University Press on behalf of the European Society of Cardiology. © European Society of Cardiology. 
AHF = acute heart failure.
1.  To improve symptoms in patients with AHF, the aggravating factors of AHF should be evaluated 
and treated (class of recommendation, I; level of evidence, B).
may worsen without adequate restriction of water or salt.18)19) Atrial fibrillation is common in 
patients with HF, and an excessively increased heart rate may be a cause of HF exacerbation 
due to increased left atrial pressure and decreased cardiac output.14) The use of medications 
such as calcium channel blockers, non-steroidal anti-inflammatory drugs, corticosteroids, 
and thiazolidinedione diabetic medications can decrease left ventricular contractility or 
worsen HF symptoms.14)
Excessive long-term alcohol consumption will deteriorate cardiac function and can 
deteriorate HF symptoms. Infections such as pneumonia and septicemia generally increase 
the metabolic demand or reduce myocardial contractility, which may exacerbate HF 
symptoms.14)20) An exacerbation of renal dysfunction or pulmonary embolism or abnormal 
production of thyroid hormones can exacerbate cardiac dysfunction. A worsening of pre-
existing heart disease such as valvular heart disease would also cause HF symptoms.14) 
Therefore, aggravating factors should be assessed and treated in all AHF patients.
Noninvasive diagnostic tests
Symptoms, physical findings, and laboratory findings in decompensated acute heart failure
The main symptoms of AHF include dyspnea, excessive body fluid retention, and fatigue, all 
of which are nonspecific findings that may occur in AHF or other cardiovascular diseases. 
The major symptoms and physical findings suggestive of AHF are summarized in Table 5. 
Because these symptoms and physical findings can be seen in other diseases, it is necessary 
to conduct differential diagnosis for pneumonia, pulmonary diseases (chronic obstructive 
pulmonary disease, pulmonary embolism, pulmonary arterial hypertension), renal 
impairment, severe infectious diseases, and acute coronary syndrome including AMI.
In patients with suspected AHF, the initial assessment should include general blood tests 
including biomarkers, electrocardiography, chest radiography, and echocardiography 
(Figure 2). Typical symptoms and signs of AHF in patients with suspected decompensated 
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1.  The initial assessment of patients with suspected AHF should include 12-lead electrocardiography, 
chest X-ray, and blood tests to evaluate the levels of blood urea nitrogen, creatinine, electrolytes, 
and serum glucose, as well as a complete blood count, a liver function test, and a thyroid 
function test (class of recommendation, I; level of evidence, C).
2.  Measuring serum natriuretic peptide levels is useful for making the clinical diagnosis in the 
presence of signs and symptoms of AHF, and especially useful for the differential diagnosis of 
AHF in patients with idiopathic dyspnea (class of recommendation, I; level of evidence, A).
3.  Echocardiography should be performed in patients with hemodynamic instability or suspected 
functional or structural heart disease (class of recommendation, I; level of evidence, C).
4.  Determining initial serum natriuretic peptide levels is useful for predicting in-hospital mortality 
and pre-discharge follow up levels is useful for assessing prognosis. (class of recommendation, I; 
level of evidence, A).
5.  Measuring the serum levels of troponin is helpful for predicting in-hospital mortality and for 
assessing prognosis (class of recommendation, I; level of evidence, A).
6.  Measuring the serum levels of ST2, a biomarker of myocardial damage or fibrosis, may be helpful 
in predicting mortality risk in patients with acute decompensated HF (class of recommendation, 
IIb; level of evidence, A).
7.  The usefulness of treatment based on serum natriuretic peptide levels has not been well 
established (class of recommendation, IIb; level of evidence, C).
AHF include the characteristic findings of fluid overload (pulmonary edema, peripheral 
edema); less often, these findings are symptoms associated with reduced cardiac output and 
decreased peripheral circulation. Because the sensitivity and accuracy of these symptoms and 
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Table 5. Major symptoms and physical findings of patients with AHF
Symptom Physical and laboratory findings
Fluid retention Orthopnea, paroxysmal nocturnal 
dyspnea, ascites, symptoms of 
gastrointestinal tract congestion
Pulmonary rales, peripheral edema, jugular 
venous distension, congestive hepatomegaly, 
hepatojugular reflux, ascites
Tissue 
hypoperfusion
Cold sweaty extremities, oliguria, 
altered mentality (confusion), dizziness
Narrow pulse pressure, metabolic acidosis, 
elevated serum lactate (>2 mmol/L), elevated 
serum creatinine, acidosis (pH <7.35)
Hypotension Systolic blood pressure <90 mmHg
Tachycardia/
Bradycardia
Heart rate >120 beats/min or <40 beats/min
Abnormal 
respiration
Respiratory rate >25 breaths/min with use of 
accessory muscles for breathing; or respiratory 
rate <8 breaths/min despite dyspnea
Hypoxemia Partial pressure of oxygen (PaO2) in arterial blood 
<80 mmHg, arterial oxygen saturation <90%
Hypercapnia Partial pressure of carbon dioxide (PaCO2) in 
arterial blood >45 mmHg
Oliguria Urine output <0.5 mL/kg/hour
AHF = acute heart failure.
Echocardiography
Symptoms and signs suggesting AHF
Patient with acute, progressive symptoms and signs
Patients with previous heart disease
High probability of HF
Investigate etiologies and
aggravating factors of AHF
Start appropriate treatment
Low probability of HF
Echocardiography can be replaced
by another, more relevant
investigation in search for the cause
of the symptoms and signs 
Abnormal ECG, chest X-ray
or
BNP≥100 pg/mL, NT-proBNP≥300 pg/mL
H
em
od
yn
am
ic
 u
ns
ta
bi
lit
y
Su
sp
ec
te
d 
st
ru
ct
ur
al
 h
ea
rt
 d
is
ea
se
Normal ECG, chest X-ray
and
BNP<100 pg/mL, NT-proBNP<300 pg/mL
ECG, chest X-ray
CBC, electrolyte, creatinine, LFT, TFT
BNP/NT-proBNP
Figure 2. Diagnostic approach for AHF. 
AHF = acute heart failure; BNP = brain natriuretic peptide; CBC = complete blood count; HF = heart failure;  
ECG = electrocardiography; LFT = liver function test; NT-proBNP = N-terminal pro-brain natriuretic peptide;  
TFT = thyroid function test.
physical findings are not high, the above-mentioned basic tests are often needed in addition 
to the clinical evaluation in order to discriminate the cause.
Baseline evaluation
1) Chest X-ray
Although pulmonary congestion, pleural effusion, and cardiomegaly are the most specific 
findings related to AHF, chest X-ray scans are normal in up to 20% of patients with AHF.21) 
Nevertheless, chest radiography can help detect non-cardiac diseases potentially responsible 
for the patients' symptoms.
2) Electrocardiography
Because patients with AHF rarely have normal findings on electrocardiography, this type 
of assessment is very helpful for identifying the underlying cardiac disease and potential 
triggering factors.22)
3) Echocardiography
An immediate echocardiographic examination is necessary only in patients with 
hemodynamic instability (cardiogenic shock), structural heart disease, or acute life-
threatening structural or functional cardiac abnormalities (acute valvular regurgitation or 
acute aortic dissection). Early echocardiography should be considered in all patients with de 
novo AHF or for whom cardiac function information is lacking. It is common for patients to 
undergo echocardiography performed by a specialist within 48 hours of admission. However, 
the optimal timing of echocardiographic assessment in AHF remains to be established. 
Repeated echocardiographic examinations are usually not needed unless a change in clinical 
condition becomes evident.
Laboratory tests
Recent routine blood tests reflect many aspects of the pathophysiology of AHF. Biomarkers 
for myocardial wall stress, hemodynamic abnormalities, inflammation, myocardial damage, 
neurohormone changes, myocardial remodeling, myocardial extracellular matrix changes, 
and myocardial fibrosis are known to provide powerful additional information for the 
standard diagnosis, treatment, and prognosis of AHF.
1) Natriuretic peptides: the brain natriuretic peptide and N-terminal pro-BNP
Sodium natriuretic peptides are used in the diagnosis or differential diagnosis of AHF, 
especially in patients with idiopathic dyspnea. The brain natriuretic peptide (BNP) and 
N-terminal pro-BNP (NT-proBNP) have high diagnostic accuracy and negative predictive 
value in patients admitted to the emergency room for acute dyspnea, and are not affected 
by ejection fraction (i.e., are useful in patients with HFrEF or HFpEF).23-29) BNP levels were 
shown to be moderately correlated with left ventricular end-diastolic pressure,30) and BNP 
levels at admission were direct predictors of in-hospital mortality, re-hospitalization within 
30 days after discharge, and subsequent re-admission and mortality in patients with AHF.31-36) 
Importantly, BNP levels immediately before discharge after HF treatment were good 
predictors of re-admission and death.27)37)38) Increased levels of natriuretic peptides are very 
useful indicators of AHF in patients with AHF-related symptoms such as dyspnea (BNP 
>100 pg/mL or NT-proBNP >300 pg/mL). However, since various cardiac and non-cardiac 
conditions can result in elevated levels of natriuretic peptides, this criterion alone cannot 
be used to establish the diagnosis of AHF (Table 6). Thus, clinical characteristics should be 
considered, along with other laboratory findings.
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The levels of natriuretic peptides decrease under treatment for HF, and the magnitude of the 
decrease is reflected in the extent of clinical improvement.36)37)39)40) Some studies have focused 
on optimizing drug therapies to lower natriuretic peptide levels has been investigated 
whether it can improve clinical outcomes compared to those attainable with standard 
HF therapy, but the prospective randomized studies conducted to date have not reported 
consistent results. Therefore, further studies are warranted to clarify the usefulness of these 
therapeutic strategies.
2) Cardiac biomarkers: troponins
The levels of troponins, which are markers of myocardial necrosis, may be increased in 
patients with AHF in the absence of AMI or obstructive coronary artery disease,41) suggesting 
that myocardial damage or necrosis persists and accumulates. It has been reported that 
AHF patients with elevated troponin levels are at an increased risk of mortality during 
hospitalization and after discharge, and that prognosis is better in patients whose troponin 
levels decrease during treatment, reflecting treatment response.32)35)40)42)
3) Markers of myocardial fibrosis: soluble ST2 and galectin-3
In combination with natriuretic peptides, soluble ST2 and galectin-3, as biomarkers of 
myocardial fibrosis, help establish the diagnosis of HF and predict the risk of hospital 
admission and death. Soluble ST2 is a product of the ST2 gene, a member of the interleukin-1 
receptor family. In animals with HF, increased ST2 transcription is associated with 
progressive myocardial fibrosis and hypertrophy induced by myocardial elongation. 
In clinical studies, soluble ST2 levels were significantly elevated in patients with AHF, 
representing a significant predictor of 1-year mortality.43)44) Galectin-3 plays an important role 
in fibroblast activation and fibrosis in animal cell models, and its elevation is associated with 
long-term survival in patients with HFrEF.45)
There is clinical evidence to support the future clinical use of biomarkers of myocardial 
damage and myocardial fibrosis in combination with already established markers such as 
natriuretic peptides. However, further studies are warranted to clarify the usefulness of such 
biomarkers for evaluating the prognosis of HF.
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Table 6. Cardiac and non-cardiac causes of elevated concentrations of natriuretic peptides
Cardiac causes Non-cardiac causes
Heart failure Advanced age
Acute coronary syndrome Ischemic stroke
Pulmonary embolism Subarachnoid hemorrhage
Myocarditis Renal dysfunction
Left ventricular hypertrophy Liver dysfunction (mainly liver cirrhosis with ascites)
Hypertrophic or restrictive cardiomyopathy Paraneoplastic syndrome
Valvular heart disease Chronic obstructive pulmonary disease
Congenital heart disease Severe infection
Atrial or ventricular tachyarrhythmia Severe burn
Cardiac contusion Anemia
Cardioversion, implantable cardioverter-
defibrillator shock
Severe metabolic or hormonal abnormalities (e.g., 
thyrotoxicosis, diabetic ketosis)
Surgical procedures involving the heart
Pulmonary hypertension
 Ponikowski P, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: 
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of 
Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, 
European Heart Journal 2016; 37 (27): 2129–2200, doi: 10.1093/eurheartj/ehw128. Reproduced by permission of 
Oxford University Press on behalf of the European Society of Cardiology. © European Society of Cardiology.
Invasive diagnostic methods
Right heart catheterization
Hemodynamic monitoring is used when it is clinically impossible to assess the fluid 
status or in patients who are unresponsive to initial therapy, especially if left ventricular 
filling pressure and cardiac output are unclear. Patients with clinically severe hypotension 
(systolic blood pressure <90 mmHg or symptomatic hypotension) and patients with renal 
impairment during initial treatment also undergo invasive hemodynamic monitoring. 
Patients indicated for heart transplantation or insertion of a mechanical circulatory assist 
device are also required to undergo right heart catheterization including the measurement 
of pulmonary vascular resistance, an essential element for evaluating the candidacy of heart 
transplantation. Invasive hemodynamic monitoring should be used in the following cases: i) 
cardiogenic shock with an increased demand for vasopressors and a mechanical circulatory 
assist device; ii) clinically significant non-compensated HF states in which treatment is 
limited due to uncertainty regarding left ventricular filling pressure, perfusion status, and 
vascular tension; iii) clinically significant dependence with vasopressor use after the initial 
clinical improvement; and iv) persistence of severe symptoms after adequate use of standard 
therapy. On the other hand, routine invasive hemodynamic monitoring is not recommended 
in patients with decompensated AHF and normal blood pressure who experience 
symptomatic improvement with diuretics and vasodilators.
Left heart catheterization
Left heart catheterization may be useful in patients with left ventricular dysfunction.
Coronary angiography
Invasive coronary angiography should be performed in patients who may need coronary 
artery reperfusion. Coronary angiography is indicated in patients who were previously 
diagnosed with coronary artery disease and angina or those with ventricular dysfunction and 
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1.  Invasive hemodynamic monitoring using a pulmonary artery catheter should be performed 
to determine the treatment direction when it is difficult to adequately assess left ventricular 
filling pressure in patients with dyspnea or hypoperfusion (class of recommendation, I; level of 
evidence, C).
2.  Invasive hemodynamic monitoring can be used in the following cases where symptoms persist 
despite standard therapy (class of recommendation, IIa; level of evidence, C):
a. Fluid status, perfusion, and systemic or pulmonary vascular resistance are uncertain
b. Systolic blood pressure remains low despite initial treatment
c. Renal function decreases after the start of treatment
d. An intravenous injection is required to raise blood pressure
e. Mechanical circulatory assist devices or heart transplantation are considered
3.  Coronary angiography and intervention should be performed if ischemia is the suspected cause of 
HF (class of recommendation, IIa; level of evidence, C).
4.  Endomyocardial biopsy may be useful in patients suspected of having a specific disease that may 
affect treatment decision (class of recommendation, IIa; level of evidence, C).
5.  Invasive hemodynamic monitoring is not recommended if pulmonary congestion symptoms 
improve after diuretic and vasodilator administration in acute non-compensated HF patients with 
normal blood pressure (class of recommendation, III; level of evidence, B).
6.  Routine endomyocardial biopsy is not recommended in patients with HF (class of 
recommendation, III; level of evidence, B).
severe coronary ischemic findings on electrocardiography or other noninvasive examinations. 
In patients without a previous diagnosis of obstructive coronary artery disease, the possibility 
of recurrent obstructive coronary artery disease should be considered if left ventricular 
dysfunction is present. In these patients, coronary angiography may help confirm the 
presence and location of coronary artery occlusion. If obstructive coronary artery disease 
has not been identified as a cause of left ventricular dysfunction, coronary angiography is 
generally unnecessary unless there is a change in clinical status suggestive of the progression 
of myocardial ischemia.
Endomyocardial biopsy
Endomyocardial biopsy is useful for diagnosing a specific disease that may affect treatment 
decision. Therefore, endomyocardial biopsy should be considered in patients with rapidly 
progressing HF or left ventricular function deterioration despite adequate medication. 
Endomyocardial biopsy should also be considered in patients with acute rejection after heart 
transplantation, infiltrative myocardial diseases (including primary amyloidosis), or acute 
myocarditis (especially if giant cell-myocarditis is suspected). However, due to the limited 
diagnostic rate and risk of procedural complications, routine endomyocardial biopsy is not 
recommended in HF.
Triage and hospitalization
AHF includes both acute de novo HF and acute exacerbations of compensated HF. In AHF, 
the mortality rate is high, and professional medical treatment such as mechanical ventilation 
is often required. Therefore, it is desirable that the patient be transferred to a specialized 
medical institution with an intensive care unit. Early diagnosis and appropriate treatment are 
critical for improving symptoms and stabilizing the patient's condition.46)47)
Classification of acute heart failure
The hemodynamic status of patients with AHF can be assessed via history taking and physical 
examination. The clinical condition is classified based on the findings of bedside physical 
examination, aiming mainly to detect clinical signs/symptoms of congestion (“wet” or 
“dry”) and/or tissue perfusion (“warm” or “cold”) according to the Forrester classification 
(Figure 1).48)49) Among these categories, “warm-dry” HF, which does not exhibit congestion 
and is characterized by good perfusion, corresponds to a stable compensated state. Patients 
with AHF most commonly exhibit congestion and good peripheral perfusion (“warm-wet” 
HF). Adequate classification of AHF at the initial evaluation is a key to accurately predicting 
prognosis and choosing the optimal treatment direction.
Initial assessment algorithm
Continuous non-invasive monitoring of the patient's condition is required at the time of the 
initial evaluation and treatment. The patient's ventilatory status, peripheral perfusion status, 
and oxygen supply should be assessed through continuous monitoring of blood pressure, 
heart rate, oxygen saturation, and urine output.50) In hemodynamically unstable conditions, 
medication or mechanically assisted circulation therapy should be considered, while 
mechanical ventilation therapy is required if the respiratory disturbance persists despite 
appropriate oxygen therapy. To prevent deterioration of the patient's condition during the 
initial treatment, it is necessary to identify and treat the triggering factors of HF, including 
acute coronary syndrome, hypertensive emergency, arrhythmia, acute structural cardiac 
damage, and acute pulmonary embolism (Figure 3).
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1) Acute coronary syndrome
In patients with acute coronary syndrome, early diagnosis and treatment are important and 
can reduce the incidence of further HF.51-59) Patients with congestive HF and acute coronary 
syndrome are at high risk and require concomitant active reperfusion therapy for acute 
coronary syndrome.56-59)
2) Hypertensive emergencies
AHF can occur with a rapid and excessive increase in arterial blood pressure and mainly 
manifests as acute pulmonary edema. In the presence of hypertensive episodes, the 
treatment for HF and that for hypertension should be performed concomitantly. Blood 
pressure should be reduced aggressively by up to 25% during the first few hours, and the use 
of intravenous vasodilators with loop diuretics is recommended for this purpose.60)61)
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Diagnostic work-to to confirm AHF
Clinical evaluation to select optimal management
Patient with suspected AHF
Cardiogenic shock?
Urgent phase
Immediate phase
(Initial 1–2 hours)
Yes
No
No
Yes
Respiratory failure?
Yes
Immediate stabilization and
transfer to ICU/CCU
Initiation of specific therapy
No
Circulatory support
· Pharmacological
· Mechanical
Ventilatory support
· Oxygen
· CPAP, BiPAP
· Mechanical ventilation
Identification of acute etiology
Acute coronary syndrome
Hypertensive emergency
Arrhythmia
(bradycardia, tachycardia,
conduction disturbance)
Acute mechanical cause†
Pulmonary embolism
·
·
·
·
·
Figure 3. Initial management strategy for AHF. 
Ponikowski P, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: 
The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of 
Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, 
European Heart Journal 2016; 37 (27): 2129–2200, doi: 10.1093/eurheartj/ehw128. Reproduced by permission of 
Oxford University Press on behalf of the European Society of Cardiology. © European Society of Cardiology. 
AHF = acute heart failure; BiPAP = bilevel positive airway pressure; CCU = coronary care unit; CPAP = continuous 
positive airway pressure; ICU = intensive care unit. 
*Acute mechanical cause: interventricular septal perforation, ventricular free wall rupture, and acute mitral 
regurgitation complicating acute coronary syndrome, ii) complications due to thoracic trauma, iii) acute native or 
prosthetic valve dysfunction secondary to endocarditis, and iv) complications due to aortic dissection or thrombosis.
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3) Arrhythmia (rapid arrhythmia or severe bradycardia/conduction disturbance)
Arrhythmia associated with hemodynamic instability is common in AHF. If serious 
arrhythmias are noted in AHF patients, they should be stabilized early using medication, 
electrical cardioversion, or a temporary pacemaker. If the patient has hemodynamic 
instability due to atrial or ventricular arrhythmias, these arrhythmias should be terminated by 
electrical cardioversion. If ventricular arrhythmias occur repeatedly, appropriate treatment is 
required. If arrhythmia is caused by myocardial ischemia, immediate reperfusion therapy is 
necessary and radiofrequency catheter ablation may be considered in some cases.62)
4) Acute mechanical causes
Acute mechanical causes include i) interventricular septal perforation, ventricular free 
wall rupture, and acute mitral regurgitation resulting from ischemic heart disease, 
ii) complications due to thoracic trauma, iii) valvular regurgitation secondary to 
acute endocarditis, and iv) complications due to aortic dissection or thrombosis. 
Echocardiographic studies play an important role in diagnosis and treatment. In patients 
with acute structural damage, hemodynamic instability or cardiogenic shock occurs 
frequently and warrants the use of circulatory assist devices; in such patients, active surgical 
correction should be considered early.63-66)
5) Acute pulmonary embolism
Reperfusion therapy using a thrombolytic agent, percutaneous catheter removal of the 
thrombus, or surgical embolectomy is recommended in patients with hypotension or 
shock.67)68) Early detection of these triggering factors of HF is important, and treatment 
should be initiated as soon as possible (within the first 1–2 hours) (Figure 3).
Treatment plan
The initial treatment plan for patients with AHF is created according to the patient's 
condition, which is defined in terms of the degree of congestion and peripheral perfusion. 
The management strategy for AHF is illustrated in Figure 4.
Criteria for hospitalization
In patients with AHF, hospitalization should be considered if there are symptoms or signs 
of congestion. The indications of hospitalization are listed in Table 7. Few patients are 
discharged from the emergency room within a few hours due to good response to the initial 
diuretic therapy. The following criteria should be considered when considering discharge 
from the emergency room:
• Have the patient’s symptoms improved sufficiently?
• Has the patient’s heart rate stabilized?
• Is orthostatic hypotension absent at standing?
• Is urine output appropriate?
• Is there any deterioration of renal function?
• Is oxygen saturation maintained (>95%)?
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If there is persistent dyspnea or hemodynamic instability, it is necessary to observe AHF 
patients in a space where cardiopulmonary resuscitation is possible. Patients with severe 
respiratory distress, hemodynamic instability, recurrent arrhythmia, and acute coronary 
syndrome are considered high risk; it is thus recommended to have such patients monitored 
and treated in the intensive care unit. Patients who meet one or more of the following criteria 
are also candidates for intensive care monitoring50):
Vasodilator
Diuretic
Ultrafiltration
(consider if
diuretic resistance)
Inotropic agent
Vasopressor
Diuretic
(when perfusion
corrected)
Mechanical
circulatory support
(if refractory)
Vasodilator
Diuretic
Inotropic agent
(if refractory)
Yes No
Wet Dry
Presence of congestion?
Vasodilator
Diuretic
·
·
·
·
·
·
·
·
·
·
·
·
Yes No
Dry and warm Dry and cold(hypovolemic)
Adjust oral
medication Fluid challenge
Hypertension
fluid redistribution
Congestion
fluid accumulation
Yes No
Hypotention(+) Hypotention(−)
Wet and warm
Patients with AHF
Wet and cold
Adequate peripheral perfusion?
Figure 4. Management strategy for AHF based on the degrees of congestion and peripheral perfusion. 
Ponikowski P, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of 
acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of 
the ESC, European Heart Journal 2016; 37 (27): 2129–2200, doi: 10.1093/eurheartj/ehw128. Reproduced by permission of Oxford University Press on behalf of the 
European Society of Cardiology. © European Society of Cardiology. 
AHF = acute heart failure.
• Decreased oxygen saturation despite oxygen supply (<90%)
• Endotracheal intubation
• Evidence of hypoperfusion 
• Use of accessory respiratory muscle during respiration, respiratory rate >25 breaths/min
• Heart rate <40 beats/min or >130 beats/min
• Systolic blood pressure <90 mmHg
CONCLUSION
As the prevalence of AHF has been increasing, AHF is a major cause of hospitalization and 
mortality. In patients with symptoms suggesting AHF, initial assessment should include 
general blood tests including biomarkers, electrocardiography, chest radiography, and 
echocardiography. Initial identification and prompt treatment of aggravating factors are 
crucial in AHF management. The management strategy should be decided based on the 
patient's status of congestion and perfusion.
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